Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 48 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Octreotide LAR Clear all
Completed Phase 3 Interventional

Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer

NCT00002864
View directory record Official record
Conditions
Breast Cancer
Interventions
octreotide acetate, tamoxifen citrate
Drug
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
Up to 120 Years · Female only
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2010
U.S. locations
2
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Octreotide in Severe Polycystic Liver Disease

NCT00426153
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Kidney, Polycystic, Abdominal Pain
Interventions
Octreotide, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 20, 2012 · Synced Sep 2, 2026, 10:55 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

NCT03972488
View directory record Official record
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor
Interventions
Lutathera, 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot), 2.5% Lys-Arg sterile amino acid solution, High dose 60 mg octreotide long-acting repeatable
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
6
States / cities
New Haven, Connecticut • Tampa, Florida • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 2 Interventional

Sandostatin LAR Depot vs. Surgery for Treating Acromegaly

NCT00001860
View directory record Official record
Conditions
Acromegaly, Pituitary Neoplasm
Interventions
Sandostatin LAR Depot versus transsphenoidal surgery
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 2 Interventional Results available

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

NCT00427349
View directory record Official record
Conditions
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neoplastic Syndrome
Interventions
AMG 706, octreotide
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
112
States / cities
Berwyn, Illinois • Chicago, Illinois • Joliet, Illinois + 78 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2023 · Synced Sep 2, 2026, 10:55 AM EDT
Recruiting Phase 4 Interventional

Hoffa's Fat Pad Impingement (HFPI)

NCT07255248
View directory record Official record
Conditions
Hoffa's Fat Pad Impingement
Interventions
methylprednisolone acetate and lidocaine, Saline injection (Octreotide LAR placebo)
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Norwood, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 1 Interventional

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

NCT03879694
View directory record Official record
Conditions
Lung Atypical Carcinoid Tumor, Lung Typical Carcinoid Tumor, Metastatic Pancreatic Neuroendocrine Tumor
Interventions
Incomplete Freund's Adjuvant, Octreotide Acetate, Sargramostim, SVN53-67/M57-KLH Peptide Vaccine
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 4 Interventional

A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly

NCT00068042
View directory record Official record
Conditions
Acromegaly
Interventions
Pegvisomant, Sandostatin LAR
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
13
States / cities
Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2008 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide

NCT03289741
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
Octreotide, LAR Lanreotide, Questionnaires
Drug · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 2 Interventional Results available

Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

NCT01121939
View directory record Official record
Conditions
Neuroendocrine Carcinoma
Interventions
Bevacizumab, Pertuzumab, Sandostatin LAR® Depot
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
9
States / cities
Fort Myers, Florida • Orlando, Florida • Augusta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 4 Interventional Results available

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

NCT01789281
View directory record Official record
Conditions
Neoplasms
Interventions
Everolimus, Sandostatin LAR Depot
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
13
States / cities
Little Rock, Arkansas • Greenwood Village, Colorado • Stamford, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 2, 2026, 10:55 AM EDT
Terminated Phase 3 Interventional

Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients

NCT00642421
View directory record Official record
Conditions
Acromegaly
Interventions
C2L-OCT-01 PR, 10 or 20 mg, C2L-OCT-01 PR, 20 mg
Drug
Lead sponsor
Ambrilia Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Los Angeles, California • Stanford, California • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2010 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)

NCT03792555
View directory record Official record
Conditions
Acromegaly
Interventions
Paltusotine, Placebo
Drug
Lead sponsor
Crinetics Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Columbus, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 2 Interventional

Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma

NCT00250796
View directory record Official record
Conditions
Liver, Cancer
Interventions
Thalidomide, alpha interferon, Thalidomide, interferon, Octreotide
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
2
States / cities
Albuquerque, New Mexico • Santa Fe, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 6, 2010 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 1 Interventional

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

NCT01204476
View directory record Official record
Conditions
Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Pancreatic Glucagonoma, Pancreatic Insulinoma, Pancreatic Polypeptide Tumor, Paraganglioma, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Merkel Cell Carcinoma, Recurrent Pancreatic Neuroendocrine Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Somatostatin-Producing Neuroendocrine Tumor, Stage III Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma, Thyroid Gland Medullary Carcinoma
Interventions
Cixutumumab, Everolimus, Laboratory Biomarker Analysis, Octreotide Acetate, Pharmacological Study
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 4 Interventional

Pediatric Hypothalamic Obesity

NCT00076362
View directory record Official record
Conditions
Obesity
Interventions
Sandostatin LAR
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
15
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2011 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 4 Interventional Results available

Surgical Debulking of Pituitary Adenomas

NCT01371643
View directory record Official record
Conditions
Pituitary Adenoma
Interventions
Octreotide LAR, transsphenoidal surgery
Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2016 · Synced Sep 2, 2026, 10:55 AM EDT
Terminated Phase 3 Interventional

Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

NCT00092287
View directory record Official record
Conditions
Malignant Carcinoid Syndrome
Interventions
lanreotide Autogel (somatostatin analogue), Sandostatin long acting release (LAR) Depot (somatostatin analogue)
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Sep 2, 2026, 10:55 AM EDT
Withdrawn Phase 1 Interventional

A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors

NCT03057509
View directory record Official record
Conditions
Small Bowel Carcinoid Tumor
Interventions
Ga-68-DOTA-TOC, Siemens PET/MR scanner, Standard Siemens Software, LAR Octreotide
Drug · Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 2 Interventional Results available

Octreotide for Management of Bronchorrhea in Mechanically Ventilated Patients

NCT02916433
View directory record Official record
Conditions
Octreotide, Sputum
Interventions
Octreotide
Drug
Lead sponsor
Danbury Hospital
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Danbury, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 4 Interventional Results available

Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis

NCT00108355
View directory record Official record
Conditions
Ascites, Cirrhosis
Interventions
Albumin, Intravenous Saline Infusion (Albumin placebo), Midodrine, Oral tablet (Midodrine placebo), Octreotide LAR, Saline injection (Octreotide LAR placebo), Large Volume Paracentesis
Drug · Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Sep 2, 2026, 10:55 AM EDT
Terminated Phase 2 Interventional

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

NCT01469338
View directory record Official record
Conditions
Diarrhea, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
cabazitaxel, prednisone, octreotide pamoate, questionnaire administration, octreotide acetate
Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2014 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 4 Interventional Results available

Effects of Sandostatin LAR® in Acromegaly

NCT01424241
View directory record Official record
Conditions
Acromegaly
Interventions
Sandostatin LAR
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Sep 2, 2026, 10:55 AM EDT
Terminated Not applicable Interventional Results available

Acromegaly Combination Treatment Study

NCT01538966
View directory record Official record
Conditions
Acromegaly
Interventions
Pegvisomant, Octreotide LAR, Lanreotide
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 2, 2026, 10:55 AM EDT